Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines

References

• Smalley R V, Weller E, Hawkins M J, Oken M M, O'Connell M J, Haase-Statz S, et al. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-a2a) plus an anthracycline-based induction regimen. Leukemia 2001; 15: 1118–1122
   PubMed Web of Science ®Google Scholar
• Weiner G J, Link B K. Monoclonal antibody therapy of B cell lymphoma. Exp Opin Biol Ther 2004; 4: 375–385
   PubMed Web of Science ®Google Scholar
• Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet 2004; 5: 292–302
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Rose A L, Smith B E, Maloney D G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002; 100: 1765–1773
   PubMed Web of Science ®Google Scholar
• Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jap J Cancer Res 1998; 89: 748–756
   PubMedGoogle Scholar
• van der Kolk L E, de Haas M, Grillo-Lopez A J, Baars J W, van Oers M HJ. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002; 16: 693–699
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituxmab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908
   PubMed Web of Science ®Google Scholar
• Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73: 213–221
   PubMed Web of Science ®Google Scholar
• Smith M R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–7368
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Czuczman M S. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol 2002; 29(Suppl 6)11–17
   PubMed Web of Science ®Google Scholar
• Coiffer B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Ghetie M A, Bright H, Vitetta E S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001; 97: 1392–1398
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800–809
   PubMed Web of Science ®Google Scholar
• Chow K U, Sommerlad W D, Boehrer S, Schneider B, Seipelt G, Rummel M J, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87: 33–43
   PubMed Web of Science ®Google Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–186
   PubMed Web of Science ®Google Scholar
• Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle-cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Thomas D A, Giles F J, Freireich E J, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–2170
   PubMed Web of Science ®Google Scholar
• Piro L D, White C A, Grillo-Lopez A J, Janakiraman N, Saven A, Beck T, Varns C, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655–661
   PubMed Web of Science ®Google Scholar
• Hegde U, White T, Stetler-Stevenson M, Marti G, Janik J, Pittaluga S, et al. Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia [abstract]. Blood 2002; 100(Suppl 1)358a
   Google Scholar
• Szollosi J, Horejsi V, Bene L, Angelisova P, Damjanovich S. Supramolecular complexes of MHC Class I, MHC Class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 1996; 157: 2939–2946
   PubMed Web of Science ®Google Scholar
• Nabhan C, Tallman M, Riley M, Fitzpatrick J, Gordon L, Gartenhaus R, et al. Phase I study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood 2001; 98: 365a
   Web of Science ®Google Scholar
• Faderl S, Thomas D A, O'Brien S, Giles F, Koller C, Beran M, et al. An exploratory study of the combination of monoclonal antibodies Campath-1H and rituximab in the treatment of CD52- and CD20- positive chronic lymphoid disorders [abstract]. Blood 2001; 98: 365a
   Web of Science ®Google Scholar
• Strauss S J, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani P L, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 3880–3886
   PubMed Web of Science ®Google Scholar
• Hu E, Epstein A L, Naeve G S, Gill I, Martin S, Sherrod A, et al. A phase 1a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 1989; 7: 155–166
   PubMed Web of Science ®Google Scholar
• Liu C, DeNardo G, Tobin E, DeNardo S. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and rituximab) on human lymphoma cells. Cancer Biother Radiopharm 2004; 19: 545
   PubMed Web of Science ®Google Scholar
• Epstein A L, Marder R J, Winter J N, Stathopoulos E, Chen F M, Parker J W, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987; 47: 830–840
   PubMed Web of Science ®Google Scholar
• Ottonello L, Morone P, Dapino P, Dallegri F. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 1996; 87: 5171–5178
   PubMed Web of Science ®Google Scholar
• Hu E, Glasky M S, Yun A, Alauddin M, Hornick J L, Khawli L A, et al. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum Antibod Hybridomas 1995; 6: 57–67
   PubMedGoogle Scholar
• Kostelny S A, Link B K, Tso J Y, Vasquez M, Jorgensen B H, Wang H, et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001; 93: 556–565
   PubMed Web of Science ®Google Scholar
• Stein R, Zhengxing Q, Chen S, Solis D, Hansen H J, Goldenberg D M. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases potency of rituximab. Neoplasia 2006; 108: 2736–2744
   Google Scholar
• Press O W, Farr A G, Borroz K I, Anderson S K, Martin P L. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989; 49: 4906–4912
   PubMed Web of Science ®Google Scholar
• Leveille C, Cataigne J G, Charron D, Al-Daccak R. MHC class II isotype-specific signaling complex on human B cells. Eur J Immunol 2002; 32: 2282–2291
   PubMed Web of Science ®Google Scholar
• Leveille C, Al-Daccak R, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999; 29: 65–74
   PubMed Web of Science ®Google Scholar
• Rose L M, Deng C T, Scott S, Xiong C Y, Lamborn K R, Gumerlock P H, et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999; 36: 789–797
   PubMed Web of Science ®Google Scholar
• Fell H P, Gayle M A, Yelton D, Lipsich L, Schieven G L, Marken J S, et al. Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 1992; 267: 15552–15558
   PubMed Web of Science ®Google Scholar
• Friberger P, Knos M, Mellstam L. Endotoxin and Their Detection with the Limulus Test. Alan R. Liss, New York 1982; 195
   Google Scholar
• Mariani A R, Columbaro M, Zauli G, Zamai L, Luchetti F, Gobbi P, et al. Lineage-related susceptibility of human hemopoietic cell lines to apoptosis. Anat Rec 1999; 254: 1–6
   PubMedGoogle Scholar
• Elsasser D, Valerius T, Repp R, Weiner G J, Deo Y, Kalden J R, et al. HLA Class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996; 87: 3803–3812
   PubMed Web of Science ®Google Scholar
• Wurflein D, Dechant M, Stockmeyer B, Tutt A L, Hu P, Repp R, et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 1998; 58: 3051–3058
   PubMed Web of Science ®Google Scholar
• Berenbaum M C. What is synergy?. Pharmacol Rev 1989; 41: 93–141
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 2868–2878
   PubMed Web of Science ®Google Scholar
• Henderson E H, Samaha R J. Evidence that drugs in multiple combinations have materially advanced the treatment of human malignancies. Cancer Res 1969; 29: 2272–2280
   Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51: 364–369
   PubMed Web of Science ®Google Scholar
• Huh Y O, Keating M, Saffer H L, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001; 116: 437–443
   PubMed Web of Science ®Google Scholar
• Jilani I, O'Brien S, Manshuri T, Thomas D A, Thomazy V A, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 3514–3520
   PubMed Web of Science ®Google Scholar
• Davis T A, Czerwinski D K, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611–615
   PubMed Web of Science ®Google Scholar
• Schmitz K, Brugger W, Weis B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999; 106: 569–674
   PubMed Web of Science ®Google Scholar
• Byrd J C, Murphy T, Howard R S, Lucas M S, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164
   PubMed Web of Science ®Google Scholar
• Semac I, Palomba C, Kulangara K, Klages N, van Echten-Deckert G, Borisch B, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003; 63: 534–540
   PubMed Web of Science ®Google Scholar
• Deans J P, Robbins S M, Polyak M J, Savage J A. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273: 344–348
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter J A, Press O W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673–683
   PubMed Web of Science ®Google Scholar
• Hofmeister J K, Cooney D, Coggeshall K. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cell Mol Dis 2000; 26: 133–143
   PubMed Web of Science ®Google Scholar
• Huby R, Dearman R J, Kimber I. Intracellular phosphotyrosine induction by major histocompatibility complex class II requires co-aggregation with membrane rafts. J Biol Chem 1999; 274: 22591–22596
   PubMed Web of Science ®Google Scholar
• Bouillon M, El Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W. Lipid raft-dependent and -independent signaling through HLA-DR molecules. J Biol Chem 2003; 278: 7099–7107
   PubMed Web of Science ®Google Scholar
• Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, et al. Effective lysis of lymphoma cells with a stabilized bi-specific single chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 2005; 130: 218–228
   PubMed Web of Science ®Google Scholar
• Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, et al. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective cell lysis of lymphoma cells. Br J Haematol 2004; 125: 167–179
   PubMed Web of Science ®Google Scholar
• Berinstein N L, Grillo-Lopez A J, White C A, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995–1001
   PubMed Web of Science ®Google Scholar